Reading few posts after CYDY sep 16th CC - best shot in near term for SP to go above $6 would be uplisting + UK conditional use for severe to critical patients + may be small revenue stream from DX test kits (sent to EU+ hope to get more orders)

Looking at M2M and HIV BLA best bet is to keep low to none on expectations with CD12 intrim results “give us momentum to cross any FDA finish line”. May be in December we might see some light.